Avantax Advisory Services Inc. Buys 8,439 Shares of Sanofi (NASDAQ:SNY)

Avantax Advisory Services Inc. increased its holdings in Sanofi (NASDAQ:SNY) by 23.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 44,507 shares of the company’s stock after buying an additional 8,439 shares during the quarter. Avantax Advisory Services Inc.’s holdings in Sanofi were worth $2,147,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Abel Hall LLC boosted its holdings in shares of Sanofi by 1.8% in the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock worth $530,000 after buying an additional 194 shares during the last quarter. Keudell Morrison Wealth Management boosted its holdings in shares of Sanofi by 1.7% in the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock worth $624,000 after buying an additional 217 shares during the last quarter. Bailard Inc. boosted its holdings in shares of Sanofi by 1.4% in the fourth quarter. Bailard Inc. now owns 16,359 shares of the company’s stock worth $789,000 after buying an additional 220 shares during the last quarter. Old Port Advisors boosted its holdings in shares of Sanofi by 0.6% in the fourth quarter. Old Port Advisors now owns 36,704 shares of the company’s stock worth $1,770,000 after buying an additional 232 shares during the last quarter. Finally, ORG Partners LLC boosted its holdings in shares of Sanofi by 17.7% in the fourth quarter. ORG Partners LLC now owns 1,681 shares of the company’s stock worth $81,000 after buying an additional 253 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $57.75 on Monday. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. Sanofi has a 1-year low of $45.22 and a 1-year high of $60.12. The company has a market capitalization of $146.56 billion, a P/E ratio of 23.19, a P/E/G ratio of 1.01 and a beta of 0.58. The firm’s 50 day simple moving average is $53.65 and its two-hundred day simple moving average is $52.81.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Research analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on SNY shares. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Sanofi has an average rating of “Buy” and an average price target of $60.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.